Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ER Y537S
i
Other names:
ESR1, Era, ESR, NR3A1, ER, ER beta
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2099
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
ER mutation (18)
ER D538G (11)
ESR1 mutation (9)
ER positive + ESR1 mutation (6)
ER Y537N (5)
ER negative + PIK3CA H1047R (2)
PIK3CA mutation + ESR1 mutation (2)
ER D538G + ER F404L (1)
ER E380Q (1)
ER E380Q + ER F404L (1)
ER F404L (1)
ER L536Q (1)
ER T594T (1)
ER Y537C (1)
ER rs2234693 (1)
ESR1 rs1801132 (1)
ESR1 rs2228480 (1)
ESR1 rs2234693T>C (1)
ESR1 rs9322354 (1)
HR positive + PIK3CA H1047R (1)
HR positive + PIK3CA H1047R + ER D538G (1)
HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G (1)
PIK3CA H1047R + PIK3CA D959N + ER E380Q (1)
PIK3CA mutation + ER mutation (1)
HER-2 negative + HR positive + ESR1 mutation + PIK3CA mutation (0)
ER mutation (18)
ER D538G (11)
ESR1 mutation (9)
ER positive + ESR1 mutation (6)
ER Y537N (5)
ER negative + PIK3CA H1047R (2)
PIK3CA mutation + ESR1 mutation (2)
ER D538G + ER F404L (1)
ER E380Q (1)
ER E380Q + ER F404L (1)
ER F404L (1)
ER L536Q (1)
ER T594T (1)
ER Y537C (1)
ER rs2234693 (1)
ESR1 rs1801132 (1)
ESR1 rs2228480 (1)
ESR1 rs2234693T>C (1)
ESR1 rs9322354 (1)
HR positive + PIK3CA H1047R (1)
HR positive + PIK3CA H1047R + ER D538G (1)
HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G (1)
PIK3CA H1047R + PIK3CA D959N + ER E380Q (1)
PIK3CA mutation + ER mutation (1)
HER-2 negative + HR positive + ESR1 mutation + PIK3CA mutation (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
ER Y537S
HER2 Negative Breast Cancer
ER Y537S
HER2 Negative Breast Cancer
H3B-6545
Sensitive: C2 – Inclusion Criteria
H3B-6545
Sensitive
:
C2
H3B-6545
Sensitive: C2 – Inclusion Criteria
H3B-6545
Sensitive
:
C2
ER Y537S
HER2 Negative Breast Cancer
ER Y537S
HER2 Negative Breast Cancer
SAR439859
Sensitive: C3 – Early Trials
SAR439859
Sensitive
:
C3
SAR439859
Sensitive: C3 – Early Trials
SAR439859
Sensitive
:
C3
ER Y537S
Estrogen Receptor Positive Breast Cancer
ER Y537S
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: C3 – Early Trials
fulvestrant
Sensitive
:
C3
fulvestrant
Sensitive: C3 – Early Trials
fulvestrant
Sensitive
:
C3
ER Y537S
HER2 Negative Breast Cancer
ER Y537S
HER2 Negative Breast Cancer
palbociclib + PF-05212384
Sensitive: C3 – Early Trials
palbociclib + PF-05212384
Sensitive
:
C3
palbociclib + PF-05212384
Sensitive: C3 – Early Trials
palbociclib + PF-05212384
Sensitive
:
C3
ER Y537S
Breast Cancer
ER Y537S
Breast Cancer
tamoxifen
Sensitive: C4 – Case Studies
tamoxifen
Sensitive
:
C4
tamoxifen
Sensitive: C4 – Case Studies
tamoxifen
Sensitive
:
C4
ER Y537S
Estrogen Receptor Positive Breast Cancer
ER Y537S
Estrogen Receptor Positive Breast Cancer
SAR439859
Sensitive: D – Preclinical
SAR439859
Sensitive
:
D
SAR439859
Sensitive: D – Preclinical
SAR439859
Sensitive
:
D
ER Y537S
Estrogen Receptor Positive Breast Cancer
ER Y537S
Estrogen Receptor Positive Breast Cancer
OP-1250
Sensitive: D – Preclinical
OP-1250
Sensitive
:
D
OP-1250
Sensitive: D – Preclinical
OP-1250
Sensitive
:
D
ER Y537S
Breast Cancer
ER Y537S
Breast Cancer
OP-1250
Sensitive: D – Preclinical
OP-1250
Sensitive
:
D
OP-1250
Sensitive: D – Preclinical
OP-1250
Sensitive
:
D
ER Y537S
Breast Cancer
ER Y537S
Breast Cancer
ZN-c5
Sensitive: D – Preclinical
ZN-c5
Sensitive
:
D
ZN-c5
Sensitive: D – Preclinical
ZN-c5
Sensitive
:
D
ER Y537S
Estrogen Receptor Positive Breast Cancer
ER Y537S
Estrogen Receptor Positive Breast Cancer
lasofoxifene
Sensitive: D – Preclinical
lasofoxifene
Sensitive
:
D
lasofoxifene
Sensitive: D – Preclinical
lasofoxifene
Sensitive
:
D
ER Y537S
Breast Cancer
ER Y537S
Breast Cancer
imlunestrant
Sensitive: D – Preclinical
imlunestrant
Sensitive
:
D
imlunestrant
Sensitive: D – Preclinical
imlunestrant
Sensitive
:
D
ER Y537S
Estrogen Receptor Positive Breast Cancer
ER Y537S
Estrogen Receptor Positive Breast Cancer
RG6171
Sensitive: D – Preclinical
RG6171
Sensitive
:
D
RG6171
Sensitive: D – Preclinical
RG6171
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.